
AbbVie’s thicket of more than 130 patents on Humira, an arthritis treatment and the world’s best-selling drug, doesn’t violate antitrust laws, the Seventh Circuit said Monday, affirming an Illinois federal court’s June 2020 ruling dismissing the lawsuit.
Settlement agreements in the US and in the European Union that permit biosimilar versions of Humira to enter the US market during 2023 “are traditional resolutions of patent litigation,” Judge Frank Easterbrook wrote in an opinion for the US Court of Appeals for the Seventh Circuit.
Even though Humira’s original patent expired in 2016, AbbVie secured and enforced more than 100 additional patents, adding many years of market exclusivity for the immunology blockbuster, court filings show. Now, as biosims near the U.S. market thanks to patent settlements between AbbVie and other companies, an appeals court has concluded that the pharma giant’s conduct was legal.
Humira generated $20.7 billion worldwide last year despite tough biosim competition already on the market in Europe.
AbbVie’s CEO Rick Gonzalez said in February that he expects the company’s earnings per share to decline in 2023, despite sales for new drugs Skyrizi and Rinvoq being on the upswing.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas